Bosentan Accord: Uses, Dosage & Side Effects
A dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension and prevention of digital ulcers in systemic sclerosis
Bosentan Accord is a prescription medication containing bosentan, a dual endothelin receptor antagonist (ERA) used primarily for the treatment of pulmonary arterial hypertension (PAH) in adults with WHO Functional Class II–III symptoms. By blocking the action of endothelin-1 – a potent vasoconstrictor and pro-proliferative peptide – on both ETA and ETB receptors in pulmonary vascular smooth muscle, bosentan reduces pulmonary vascular resistance, improves exercise capacity, and slows disease progression. It is also indicated for reducing the development of new digital ulcers in patients with systemic sclerosis (scleroderma). Bosentan requires careful monitoring due to its risk of hepatotoxicity and teratogenicity, and is available only through restricted distribution programs in some countries.
Quick Facts: Bosentan Accord
Key Takeaways
- Bosentan Accord is a dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) in adults with WHO Functional Class II–III symptoms, shown to improve exercise capacity and slow clinical worsening.
- Monthly liver function monitoring is mandatory because bosentan can cause dose-dependent elevations in liver enzymes (aminotransferases), occurring in approximately 11% of patients, which are generally reversible upon dose adjustment or discontinuation.
- Bosentan is a known teratogen (Pregnancy Category X) and is strictly contraindicated during pregnancy; women of childbearing potential must use two reliable forms of contraception, and monthly pregnancy tests are recommended.
- Significant drug interactions occur with cyclosporine A (contraindicated), glibenclamide (not recommended), hormonal contraceptives (reduced effectiveness), and several CYP-metabolized drugs including sildenafil, warfarin, and statins.
- Treatment is started at 62.5 mg twice daily for 4 weeks then uptitrated to the maintenance dose of 125 mg twice daily; dose adjustments are required for hepatic impairment and when liver enzymes are elevated.
What Is Bosentan Accord and What Is It Used For?
Bosentan Accord is a generic medicine containing the active substance bosentan, which belongs to the pharmacological class of endothelin receptor antagonists (ERAs). It is bioequivalent to the originator product Tracleer, developed by Actelion Pharmaceuticals (now part of Janssen/Johnson & Johnson). Bosentan was the first oral ERA approved for the treatment of pulmonary arterial hypertension (PAH), receiving its initial marketing authorization from the FDA in November 2001 and from the EMA in 2002. Its introduction represented a paradigm shift in the management of PAH, a previously untreatable and rapidly fatal disease.
Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstrictors known, produced predominantly by vascular endothelial cells. In addition to its vasoconstrictive properties, ET-1 promotes smooth muscle cell proliferation, fibrosis, and inflammation in blood vessel walls. ET-1 exerts its effects through two receptor subtypes: the endothelin A (ETA) receptor, found primarily on vascular smooth muscle cells, and the endothelin B (ETB) receptor, expressed on both endothelial cells and smooth muscle cells. Activation of ETA receptors on smooth muscle leads to potent vasoconstriction and cell proliferation, while ETB receptors on endothelial cells mediate the release of nitric oxide and prostacyclin (promoting vasodilation and antiproliferation), though ETB receptors on smooth muscle also contribute to vasoconstriction.
In patients with pulmonary arterial hypertension, the endothelin system is pathologically activated. Plasma levels of ET-1 are significantly elevated, and overexpression of ET-1 in pulmonary vascular tissue drives progressive vasoconstriction, vascular remodeling (intimal thickening, medial hypertrophy, and in situ thrombosis), and ultimately right heart failure. This dysregulation of the endothelin pathway is a central feature of PAH pathobiology and represents a primary therapeutic target.
Bosentan acts as a dual (non-selective) endothelin receptor antagonist, blocking both ETA and ETB receptors with a slightly higher affinity for ETA (approximately 20-fold). By antagonizing both receptor subtypes, bosentan comprehensively blocks the detrimental effects of endothelin-1 on the pulmonary vasculature. This results in decreased pulmonary vascular resistance, reduced mean pulmonary arterial pressure, and improved cardiac output. The combined blockade of both receptor subtypes may offer therapeutic advantages over selective ETA antagonists by preventing ETB-mediated vasoconstriction on smooth muscle while accepting the loss of ETB-mediated vasodilation on endothelial cells.
Approved Indications
Bosentan is approved for two primary indications:
- Pulmonary arterial hypertension (PAH): Treatment of PAH in adults classified as WHO Functional Class II (mild limitation of physical activity) and Class III (marked limitation of physical activity). Efficacy has been demonstrated in idiopathic PAH, PAH associated with connective tissue diseases (particularly systemic sclerosis), and PAH associated with congenital heart disease with Eisenmenger physiology. In the EU, bosentan is also approved for PAH in pediatric patients aged 1 year and older.
- Digital ulcers in systemic sclerosis: Reduction of the number of new digital ulcers in patients with systemic sclerosis who have ongoing digital ulcer disease. This indication is based on the RAPIDS-2 trial, which showed that bosentan reduced the formation of new digital ulcers by approximately 30% compared with placebo.
The pivotal clinical evidence supporting bosentan's use in PAH comes from multiple randomized controlled trials. The BREATHE-1 trial (Bosentan Randomized Trial of Endothelin Antagonist Therapy), published in The Lancet in 2001, enrolled 213 patients with PAH (WHO Functional Class III–IV). After 16 weeks, patients treated with bosentan 125 mg twice daily demonstrated a statistically significant improvement in 6-minute walk distance (6MWD) of 44 meters compared with placebo. Bosentan also significantly delayed time to clinical worsening, a composite endpoint including death, hospitalization for PAH, or need for additional PAH therapy. The EARLY trial (2008) extended these findings to WHO Functional Class II patients, demonstrating that early treatment with bosentan significantly reduced pulmonary vascular resistance and delayed clinical progression compared with placebo.
According to the 2022 ESC/ERS Guidelines for Pulmonary Hypertension, endothelin receptor antagonists including bosentan are recommended as first-line therapy for PAH patients with low or intermediate risk profiles (Class I recommendation, Level A evidence). Bosentan is frequently used in combination with phosphodiesterase-5 inhibitors (such as sildenafil or tadalafil) and/or prostacyclin pathway agents as part of a goal-oriented treatment strategy.
What Should You Know Before Taking Bosentan Accord?
Contraindications
Bosentan must not be used in the following situations:
- Pregnancy: Bosentan is classified as Pregnancy Category X (teratogenic). Animal studies have shown severe birth defects including malformations of the head, face, and large blood vessels at all doses tested. Bosentan must not be used during pregnancy under any circumstances.
- Hypersensitivity: Known allergy to bosentan or any of the excipients in the formulation.
- Severe hepatic impairment: Patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) must not use bosentan due to the significantly increased risk of hepatotoxicity.
- Baseline elevated liver enzymes: Patients with baseline aminotransferase levels (ALT/AST) exceeding 3 times the upper limit of normal (ULN) should not initiate bosentan therapy.
- Concomitant use with cyclosporine A: Co-administration is contraindicated because cyclosporine A significantly increases bosentan plasma concentrations (approximately 30-fold increase in trough levels), increasing the risk of serious adverse effects.
- Concomitant use with glibenclamide (glyburide): Co-administration is not recommended due to increased risk of liver enzyme elevations and reduced efficacy of both medications.
Warnings and Precautions
Several important safety considerations must be addressed before and during bosentan treatment:
Hepatotoxicity: Bosentan causes dose-dependent elevations in liver aminotransferases (ALT and AST). In clinical trials, approximately 11% of patients experienced aminotransferase elevations exceeding 3 times the upper limit of normal (3× ULN), and approximately 4% exceeded 8× ULN. Most elevations occurred within the first 26 weeks of therapy but could arise at any time during treatment. In the majority of cases, liver enzyme elevations were asymptomatic and resolved either spontaneously, after dose reduction, or after treatment discontinuation. However, rare cases of severe hepatotoxicity with liver failure have been reported. Liver function tests (ALT and AST) must be measured before initiating treatment and then at least monthly thereafter. If aminotransferases rise above 3× ULN, the dose should be reduced or treatment stopped, with more frequent monitoring until values normalize.
Liver aminotransferases (ALT/AST) must be measured before starting treatment and at least monthly during treatment. If ALT/AST exceed 3× ULN: confirm with a repeat test within 2 weeks. If confirmed at 3–5× ULN: reduce dose or stop treatment and monitor at least every 2 weeks until values normalize. If ALT/AST exceed 5× ULN: discontinue bosentan immediately. Do not restart unless ALT/AST return to pretreatment values and the benefit clearly outweighs the risk.
Hemoglobin and hematocrit decrease: Bosentan causes a dose-related decrease in hemoglobin concentration (mean reduction of approximately 0.9 g/dL from baseline) and hematocrit. This effect is thought to be related to hemodilution rather than true red blood cell destruction. Hemoglobin levels should be checked after 1 and 3 months of treatment and quarterly thereafter. In most cases, hemoglobin stabilizes or improves slightly during continued treatment, but clinically significant anemia has been reported in approximately 3–6% of patients in clinical trials.
Fluid retention and edema: Bosentan may cause fluid retention and peripheral edema, particularly during the first weeks of treatment. This effect is related to the drug’s vasodilatory action and may require initiation or adjustment of diuretic therapy. Patients with underlying cardiac conditions should be monitored closely for signs of fluid overload.
Pulmonary veno-occlusive disease (PVOD): If signs of pulmonary edema develop during bosentan therapy, the possibility of pulmonary veno-occlusive disease should be considered. Bosentan has not been studied in PVOD, and vasodilators may worsen this condition. Treatment should be discontinued if PVOD is confirmed.
Pregnancy and Breastfeeding
Bosentan is absolutely contraindicated during pregnancy. It is classified as a teratogen based on extensive animal data showing malformations of the head, face, and cardiovascular system at all doses tested. There are no adequate and well-controlled studies in pregnant women, and the drug must not be used at any stage of pregnancy.
Women of childbearing potential must meet the following requirements before and during bosentan treatment:
- A negative pregnancy test must be obtained before starting treatment.
- Two reliable methods of contraception must be used simultaneously throughout treatment and for at least one month after discontinuation. Hormonal contraceptives alone are not considered reliable because bosentan reduces their effectiveness (see Drug Interactions section).
- Monthly pregnancy tests are recommended during treatment.
- If pregnancy occurs during treatment, bosentan must be discontinued immediately, and the patient should be informed about the serious risk to the fetus.
It is not known whether bosentan is excreted in human breast milk. Bosentan and its metabolites have been detected in the milk of lactating rats. Breastfeeding is not recommended during treatment with bosentan due to the potential for serious adverse reactions in the nursing infant.
Bosentan may affect male fertility. In animal studies, bosentan caused testicular atrophy and impaired spermatogenesis at high doses. In clinical observations, reduced sperm counts have been reported in some men taking bosentan, though the effect appears to be reversible after discontinuation. Men should be counseled about this potential risk before starting therapy.
How Does Bosentan Accord Interact with Other Drugs?
Bosentan is metabolized in the liver primarily by cytochrome P450 enzymes CYP2C9 and CYP3A4. It is also a moderate inducer of these same enzymes, meaning it can increase the metabolism of other drugs that are substrates for CYP2C9 and CYP3A4, potentially reducing their plasma concentrations and therapeutic effectiveness. Additionally, bosentan is a substrate of the hepatic uptake transporters OATP1B1 and OATP1B3, and inhibitors of these transporters can significantly increase bosentan exposure. This complex pharmacokinetic profile underlies the numerous clinically relevant drug interactions associated with bosentan therapy.
Major Interactions
| Drug | Effect | Clinical Significance | Recommendation |
|---|---|---|---|
| Cyclosporine A | Bosentan trough levels increased ~30-fold; cyclosporine levels decreased ~50% | Greatly increased risk of bosentan toxicity; reduced immunosuppression | Contraindicated |
| Glibenclamide (Glyburide) | Increased risk of elevated liver enzymes; potential reduction of hypoglycemic effect | Increased hepatotoxicity risk and reduced diabetes control | Not recommended; use alternative antidiabetics |
| Fluconazole | Inhibits CYP2C9 and CYP3A4; significantly increases bosentan plasma concentrations | Increased risk of bosentan toxicity including hepatotoxicity | Not recommended; use alternative antifungals |
Clinically Important Interactions
| Drug | Effect | Recommendation |
|---|---|---|
| Hormonal contraceptives | Bosentan induces CYP3A4, reducing plasma levels of ethinylestradiol and norethisterone by ~30–50% | Use two methods of contraception; add barrier method or copper IUD |
| Sildenafil | Bosentan reduces sildenafil levels by ~63%; sildenafil increases bosentan levels by ~50% | Monitor efficacy of both drugs; dose adjustment may be needed |
| Rifampicin | Rifampicin initially increases then decreases bosentan levels through CYP induction; unpredictable effect | Monitor liver function closely; avoid if possible |
| Warfarin | Bosentan induces CYP2C9, potentially decreasing warfarin exposure and INR | Monitor INR closely; adjust warfarin dose as needed |
| Simvastatin and other statins | Bosentan reduces simvastatin levels by ~50% through CYP3A4 induction | Monitor cholesterol; consider statin dose increase or alternative |
| Ketoconazole | Inhibits CYP3A4; increases bosentan plasma levels by approximately 2-fold | No dose adjustment needed but monitor liver function |
| Tacrolimus / Sirolimus | Bosentan may reduce levels of these immunosuppressants through CYP3A4 induction | Monitor blood levels of immunosuppressant and adjust dose |
The interaction between bosentan and sildenafil is of particular clinical relevance because both drugs are frequently used together in the treatment of PAH as part of combination therapy. The COMPASS-2 trial evaluated the addition of bosentan to sildenafil in PAH patients and demonstrated that while the pharmacokinetic interaction reduces sildenafil levels, the clinical combination can still provide benefit. However, physicians should be aware that the reduced sildenafil exposure may require dose optimization.
Patients should always inform their prescriber and pharmacist about all medications they are taking, including prescription drugs, over-the-counter medications, herbal products (particularly St. John’s wort, which is a CYP3A4 inducer), and dietary supplements. The complex enzyme-inducing properties of bosentan mean that new interactions may emerge when medications are added or removed from a patient’s regimen.
What Is the Correct Dosage of Bosentan Accord?
Adults
Standard Adult Dosing
Initiation phase (first 4 weeks): 62.5 mg twice daily (morning and evening), taken orally with or without food. This lower starting dose is used to minimize the risk of hepatotoxicity and allows the body to adjust to the medication.
Maintenance phase (from week 5 onwards): 125 mg twice daily (morning and evening). This is the target maintenance dose for most adult patients weighing more than 40 kg.
Patients weighing 40 kg or less: The recommended initial and maintenance dose is 62.5 mg twice daily. No uptitration is recommended.
Treatment with bosentan should only be initiated and monitored by physicians experienced in the management of pulmonary arterial hypertension. The need for continued treatment should be reassessed regularly based on clinical response, hemodynamic parameters, and functional capacity assessments. There is limited clinical experience with doses exceeding 125 mg twice daily in adults, and higher doses have not shown additional benefit.
Children
Pediatric Dosing (EU Approval, 1 Year and Older)
Pediatric dosing is based on body weight. A dispersible tablet formulation (32 mg) is available for children who cannot swallow film-coated tablets.
- Body weight 10–20 kg: 31.25 mg (half of 62.5 mg tablet or one 32 mg dispersible tablet) twice daily for 4 weeks, then maintenance at the same dose.
- Body weight 20–40 kg: 62.5 mg twice daily for 4 weeks, then maintenance at the same dose.
- Body weight >40 kg: Follow adult dosing (62.5 mg twice daily for 4 weeks, then 125 mg twice daily).
Pediatric dosing in the United States is not specifically FDA-approved; off-label use follows similar weight-based recommendations.
Elderly
No dose adjustment is required for elderly patients based on age alone. However, elderly patients may be more susceptible to hepatotoxicity and may have age-related decline in hepatic and renal function. More frequent monitoring of liver function and clinical response is recommended. The standard initiation and maintenance dosing protocol applies.
Dose Adjustment for Hepatic Impairment
Bosentan is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). For patients with mild hepatic impairment (Child-Pugh Class A), no dose adjustment is required, but more frequent monitoring of liver function (every 2 weeks) is recommended. In all patients, if liver aminotransferases (ALT/AST) exceed 3× ULN during treatment, dose reduction or discontinuation is necessary according to the hepatotoxicity monitoring protocol.
Missed Dose
If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Patients should never take a double dose to compensate for a missed dose. Consistent twice-daily dosing helps maintain stable plasma concentrations and optimal therapeutic effect. If multiple doses are missed, patients should contact their healthcare provider for guidance on restarting therapy.
Overdose
There is limited clinical experience with bosentan overdose. In healthy volunteers, single doses of up to 2,400 mg were administered and caused headache, nausea, and vomiting. In the event of an overdose, standard supportive measures should be implemented. The most likely symptoms would include significant hypotension, which may require vasopressor support and intravenous fluid administration. Due to bosentan’s high protein binding (>98%), hemodialysis is unlikely to be effective in removing the drug from the body. Patients who have taken an overdose should be monitored closely with frequent assessment of blood pressure, heart rate, liver function, and hemoglobin levels.
Abrupt withdrawal of bosentan has not been associated with a rebound effect in clinical experience. However, gradual dose reduction (halving the dose for 3–7 days before stopping) is generally recommended to minimize the theoretical risk of clinical deterioration. Close monitoring is essential after discontinuation, as PAH is a progressive disease and patients may experience clinical worsening when active therapy is stopped.
What Are the Side Effects of Bosentan Accord?
Like all medicines, bosentan can cause side effects, although not everybody experiences them. The safety profile of bosentan has been extensively characterized through clinical trials involving over 2,000 patients and more than 20 years of post-marketing surveillance. Side effects are listed below by frequency category according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (<1/1,000).
Very Common
Affects more than 1 in 10 people
- Headache
- Edema (fluid retention, swollen ankles and legs)
- Elevated liver aminotransferases (ALT/AST increases)
- Anemia or decreased hemoglobin
Common
Affects 1 to 10 in 100 people
- Hypotension (low blood pressure)
- Palpitations
- Syncope (fainting)
- Flushing
- Nasal congestion
- Gastroesophageal reflux disease
- Diarrhea
- Pruritus (itching)
- Fatigue
- Chest pain
Uncommon
Affects 1 to 10 in 1,000 people
- Thrombocytopenia (low platelet count)
- Neutropenia (low white blood cell count)
- Elevated bilirubin
- Anaphylaxis / angioedema
- Liver cirrhosis or liver failure
- Rash
Rare
Affects fewer than 1 in 1,000 people
- Severe hepatotoxicity with liver failure (including fatal cases)
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Jaundice (unexplained)
The most clinically significant adverse effect of bosentan is hepatotoxicity, manifested as dose-dependent elevations in liver aminotransferases. In controlled clinical trials, approximately 11% of bosentan-treated patients experienced aminotransferase elevations >3× ULN compared with approximately 2% on placebo. The mechanism is thought to involve inhibition of the bile salt export pump (BSEP), leading to intrahepatic cholestasis and hepatocellular injury. In the vast majority of cases, liver enzyme elevations are reversible upon dose reduction or discontinuation, though rare cases of irreversible liver damage and fatal liver failure have been reported in post-marketing surveillance.
The decrease in hemoglobin observed with bosentan therapy is generally mild (mean decrease of approximately 0.9 g/dL) and is attributed primarily to fluid retention and hemodilution rather than direct bone marrow suppression. However, in rare cases, hemoglobin levels may fall to clinically significant levels (<10 g/dL), requiring further investigation and potentially blood transfusion. Hemoglobin should be monitored after 1 month, 3 months, and quarterly thereafter.
Peripheral edema is common during bosentan therapy and may worsen in patients with underlying cardiac conditions. In clinical practice, approximately 5–8% of patients require the addition of a diuretic to manage fluid retention. The edema usually develops within the first weeks of treatment and may stabilize or improve over time without intervention in mild cases.
Contact your doctor immediately or go to the nearest emergency department if you experience: unexplained nausea, vomiting, right upper abdominal pain, fatigue, or jaundice (yellowing of the skin or eyes) – these may indicate severe liver injury; severe allergic reactions including difficulty breathing, swelling of the face, lips, tongue, or throat; severe skin reactions with blistering or peeling; or sudden worsening of your breathing or new cough – which could indicate pulmonary edema.
How Should You Store Bosentan Accord?
Bosentan Accord film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). Keep the tablets in the original blister packaging until ready for use to protect from moisture exposure. Do not store in the bathroom or near a sink, as humidity can degrade the medication. The tablets should be kept in a safe location that is out of reach and sight of children, as accidental ingestion by a child could be extremely dangerous given the drug’s teratogenic potential.
Do not use Bosentan Accord after the expiry date stated on the carton and blister after “EXP.” The expiry date refers to the last day of that month. Inspect the tablets before use; do not take any tablets that appear discolored, cracked, or otherwise damaged. If in doubt about the integrity of the medication, consult your pharmacist.
Do not dispose of unused medicines via wastewater or household waste. Ask your pharmacist about how to properly dispose of medicines you no longer need. Given the teratogenic properties of bosentan, proper disposal is especially important to prevent accidental exposure. In many countries, pharmaceutical take-back programs are available at pharmacies for the safe disposal of unused or expired medications.
What Does Bosentan Accord Contain?
Active ingredient: Each Bosentan Accord 62.5 mg film-coated tablet contains 62.5 mg of bosentan (as bosentan monohydrate). Each Bosentan Accord 125 mg film-coated tablet contains 125 mg of bosentan (as bosentan monohydrate). Bosentan monohydrate is a white to off-white crystalline powder with the molecular formula C27H29N5O6S·H2O and a molecular weight of 569.6 g/mol (monohydrate form).
Inactive ingredients (excipients):
- Tablet core: Pregelatinized starch (maize), sodium starch glycolate (Type A), povidone K-30, glycerol dibehenate, magnesium stearate.
- Film coating: Hypromellose, glycerol triacetate (triacetin), talc, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172). The exact coloring agents may differ between the 62.5 mg and 125 mg tablets to allow visual differentiation.
The 62.5 mg tablets are typically round, biconvex, pale orange to light orange film-coated tablets debossed with an identification mark. The 125 mg tablets are typically oval, biconvex, orange to dark orange film-coated tablets with a score line on one side and debossed identification mark. The score line is to facilitate breaking for ease of swallowing and is not intended to divide into equal doses.
Patients with known allergies to any of the listed excipients should inform their physician before starting treatment. The formulation contains sodium starch glycolate, which contains sodium; patients on a controlled sodium diet should be advised of this, although the sodium content per tablet is very small.
Frequently Asked Questions About Bosentan Accord
Bosentan Accord is used to treat pulmonary arterial hypertension (PAH) in adults classified as WHO Functional Class II–III. It improves exercise capacity and slows disease progression by blocking the endothelin receptors in the pulmonary blood vessels, thereby reducing pulmonary vascular resistance and pressure. It is also indicated for reducing the number of new digital ulcers in patients with systemic sclerosis (scleroderma) who have ongoing digital ulcer disease.
Bosentan can cause dose-dependent elevations in liver enzymes (ALT and AST), which occurred in approximately 11% of patients in clinical trials. Monthly monitoring allows early detection of liver injury before it becomes severe. If elevated enzymes are caught early, dose reduction or temporary discontinuation usually allows the liver to recover. Rare cases of severe liver failure have been reported, making regular monitoring essential for your safety throughout the course of treatment.
No, absolutely not. Bosentan is a known teratogen (Pregnancy Category X) and is strictly contraindicated during pregnancy. It has been shown to cause severe birth defects in animal studies at all doses tested, including malformations of the head, face, and cardiovascular system. Women of childbearing potential must use two reliable methods of contraception during treatment and for at least one month after stopping. Hormonal contraceptives alone are insufficient because bosentan reduces their effectiveness. Monthly pregnancy tests are recommended during treatment.
Bosentan Accord is a generic version of the original branded product Tracleer, both containing the same active substance bosentan at the same strengths. Generic medicines must demonstrate bioequivalence to the reference product through rigorous regulatory testing, meaning they deliver the same amount of active substance at the same rate. The efficacy, safety, and quality are considered equivalent by regulatory authorities (EMA, FDA). The primary differences may include the excipients used in the tablet formulation and the cost, with generic versions typically being more affordable.
Yes, combination therapy with bosentan and sildenafil (or tadalafil) is a well-established treatment approach for PAH and is recommended in current ESC/ERS guidelines. However, there is a pharmacokinetic interaction: bosentan reduces sildenafil plasma levels by approximately 63% through CYP3A4 induction, while sildenafil increases bosentan levels by approximately 50%. Despite this interaction, the combination has shown clinical benefits in multiple studies. Your doctor will monitor the effectiveness of both drugs and may adjust doses accordingly.
Some patients may notice initial improvements in symptoms within the first 4 weeks of treatment, but the full therapeutic effect is typically evaluated at 12 to 16 weeks. In pivotal clinical trials, statistically significant improvements in 6-minute walk distance were demonstrated at 16 weeks. Remember that the first 4 weeks involve a lower starting dose (62.5 mg twice daily) before uptitrating to the maintenance dose (125 mg twice daily). Your doctor will assess your response through exercise testing, echocardiography, and clinical evaluation of your functional class.
References
- European Medicines Agency (EMA). Tracleer (bosentan) – Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Tracleer (bosentan) tablets – Prescribing Information. Revised 2024.
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237.
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study (BREATHE-1). The Lancet. 2001;358(9288):1119–1123.
- Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet. 2008;371(9630):2093–2100.
- Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 2011;70(1):32–38.
- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology. 2009;53(17):1573–1619.
- World Health Organization. WHO Model List of Essential Medicines – 23rd list (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Bosentan. National Institute for Health and Care Excellence (NICE). Last reviewed 2025.
- Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124(1):247–254.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Pulmonology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of medical experts reviewing content according to ESC/ERS, EMA, and FDA guidelines
Evidence Framework
GRADE evidence assessment – Level 1A based on systematic reviews and randomized controlled trials
Editorial Standards
Independent medical information – No commercial funding or pharmaceutical sponsorship
Disclaimer: This article is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider before starting, changing, or stopping any medication. The information presented here is based on the latest available evidence as of the date of last review and may be subject to updates as new data becomes available.